JP2007063144A - Liquid composition - Google Patents
Liquid composition Download PDFInfo
- Publication number
- JP2007063144A JP2007063144A JP2005247332A JP2005247332A JP2007063144A JP 2007063144 A JP2007063144 A JP 2007063144A JP 2005247332 A JP2005247332 A JP 2005247332A JP 2005247332 A JP2005247332 A JP 2005247332A JP 2007063144 A JP2007063144 A JP 2007063144A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- decenoic acid
- liquid composition
- surfactant
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- KUPHXIFBKAORGY-UHFFFAOYSA-N 2-amino-3-iodo-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(N)=C1I KUPHXIFBKAORGY-UHFFFAOYSA-N 0.000 claims abstract description 26
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 claims abstract description 26
- -1 polyoxyethylene group Polymers 0.000 claims abstract description 26
- 239000004094 surface-active agent Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 5
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 3
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 3
- 240000008067 Cucumis sativus Species 0.000 claims description 7
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 7
- 241000411851 herbal medicine Species 0.000 claims description 7
- 241000190633 Cordyceps Species 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 241000533367 Cnidium officinale Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 229940109850 royal jelly Drugs 0.000 description 8
- 239000002904 solvent Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000981595 Zoysia japonica Species 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、１０−ヒドロキシ−２−デセン酸が安定化された液体組成物に関する。 The present invention relates to a liquid composition in which 10-hydroxy-2-decenoic acid is stabilized.
１０−ヒドロキシ−２−デセン酸は、ローヤルゼリーに特異的に含まれている有機酸であり、抗腫瘍作用、菌発育阻止作用を持つと言われている。ローヤルゼリーは蛋白質、脂質、炭水化物をはじめ、ビタミン類、ミネラル類、アミノ酸類、脂肪酸等の栄養成分をバランスよく含み、滋養、強壮、体質改善等広範な薬理作用を示すなど高度の機能性を有することから健康食品、医薬品、化粧品として利用されている。 10-Hydroxy-2-decenoic acid is an organic acid specifically contained in royal jelly, and is said to have antitumor activity and fungal growth inhibition activity. Royal jelly contains protein, lipid, carbohydrates, vitamins, minerals, amino acids, fatty acids and other nutritional components in a well-balanced manner, and has a high degree of functionality such as nourishment, toughness, constitution improvement, etc. It is used as health food, pharmaceuticals and cosmetics.
しかしながら、１０−ヒドロキシ−２−デセン酸の安定性に関する研究は、ほとんど行われておらず、単一水溶液（クエン酸緩衝液）中では安定であるが、ドリンク剤等の製剤に他の成分と共に配合した場合に、その安定性が損なわれることが知られていた。 However, there has been almost no research on the stability of 10-hydroxy-2-decenoic acid, and it is stable in a single aqueous solution (citrate buffer). It has been known that when blended, the stability is impaired.
従来、栄養補給や疾病の治療等を目的として、ビタミンＡ、ビタミンＥ等の脂溶性薬物がドリンク剤等の液剤に配合されているが、このような脂溶性薬物を液剤に安定に配合するためには、可溶化剤として界面活性剤を添加する必要がある。一般的に、ドリンク剤のような内服液剤においては、安全性の観点から、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレングリセリン脂肪酸エステル等が用いられている（特許文献１参照）。 Conventionally, fat-soluble drugs such as vitamin A and vitamin E have been blended into liquids such as drinks for the purpose of nutritional supplementation and disease treatment, etc., in order to stably blend such fat-soluble drugs into liquids. It is necessary to add a surfactant as a solubilizer. Generally, in an internal liquid such as a drink, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene glycerin fatty acid ester and the like are used from the viewpoint of safety (Patent Document 1). reference).
また、従来、ローヤルゼリーを配合したドリンク剤（特許文献２参照）が知られているが、１０−ヒドロキシ−２−デセン酸と、ビタミンＡ、ビタミンＥ等の脂溶性薬物を配合した液剤については知られていない。 Conventionally, drinks containing royal jelly (see Patent Document 2) are known, but liquids containing 10-hydroxy-2-decenoic acid and fat-soluble drugs such as vitamin A and vitamin E are known. It is not done.
本発明者らが脂溶性薬物及びローヤルゼリーを配合したドリンク剤を開発しようとしたところ、以下の欠点が判明した。すなわち、１０−ヒドロキシ−２−デセン酸と、脂溶性薬物の可溶化剤であるポリオキシエチレン基を有する界面活性剤を液剤に配合することにより、１０−ヒドロキシ−２−デセン酸の安定性が著しく低下することが判明した。 When the present inventors tried to develop a drink containing a fat-soluble drug and royal jelly, the following drawbacks were found. That is, by adding 10-hydroxy-2-decenoic acid and a surfactant having a polyoxyethylene group, which is a solubilizer of a fat-soluble drug, to the liquid agent, the stability of 10-hydroxy-2-decenoic acid is improved. It turned out to be significantly reduced.
本発明は、ポリオキシエチレン基を有する界面活性剤が配合されていても１０−ヒドロキシ−２−デセン酸の安定性が改善された液体組成物を提供することを目的とする。 An object of the present invention is to provide a liquid composition in which the stability of 10-hydroxy-2-decenoic acid is improved even when a surfactant having a polyoxyethylene group is blended.
上記課題を解決するために、本発明者は鋭意検討を重ねた結果、白ジュツ、川キュウ、冬虫夏草、柴胡からなる群より選ばれる１種又は２種以上を配合することにより、ポリオキシエチレン基を有する界面活性剤を含有する溶液中で１０−ヒドロキシ−２−デセン酸を安定化できることを見出し、本発明を完成した。 In order to solve the above-mentioned problems, the present inventor has conducted extensive studies, and as a result, polyoxyethylene is blended by blending one or more selected from the group consisting of white jutsu, river cucumber, cordyceps, and shiihu. The present invention was completed by finding that 10-hydroxy-2-decenoic acid can be stabilized in a solution containing a surfactant having a group.
すなわち、本発明は以下の通りである。
（１）白ジュツ、川キュウ、冬虫夏草、柴胡からなる群より選ばれる１種又は２種以上の生薬、１０-ヒドロキシ-２-デセン酸、及び、ポリオキシエチレン基を有する界面活性剤を含有する液体組成物。
（２）ポリオキシエチレン基を有する界面活性剤が、ポリオキシエチレン硬化ヒマシ油である上記（１）に記載の液体組成物。
（３）ポリオキシエチレン基を有する界面活性剤と１０-ヒドロキシ-２-デセン酸を含む液体組成物に、白ジュツ、川キュウ、冬虫夏草、柴胡からなる群より選ばれる１種又は２種以上の生薬を添加することによる１０-ヒドロキシ-２-デセン酸の安定化方法。
That is, the present invention is as follows.
(1) Contains one or more herbal medicines selected from the group consisting of white jutsu, river cucumber, cordyceps sinensis, and shiihu, 10-hydroxy-2-decenoic acid, and a surfactant having a polyoxyethylene group Liquid composition.
(2) The liquid composition according to the above (1), wherein the surfactant having a polyoxyethylene group is polyoxyethylene hydrogenated castor oil.
(3) A liquid composition containing a surfactant having a polyoxyethylene group and 10-hydroxy-2-decenoic acid, one or more selected from the group consisting of white jutsu, river cucumber, cordyceps and saiko Of 10-hydroxy-2-decenoic acid by adding a crude drug of
本発明により、ポリオキシエチレン基を有する界面活性剤を配合した液体組成物においても１０−ヒドロキシ−２−デセン酸を安定に配合することができた。 According to the present invention, 10-hydroxy-2-decenoic acid can be stably blended even in a liquid composition blended with a surfactant having a polyoxyethylene group.
本発明で用いる１０−ヒドロキシ−２−デセン酸は、公知の化合物であり、ローヤルゼリーからの抽出物もしくは合成品のいずれであってもよく、又は、これを含むローヤルゼリーの形態で配合されてもよい。その配合量は、製剤全体に対して、１×１０-5〜１．０ｗ/ｖ％、好ましくは1×１０-5〜1×１０-1ｗ/ｖ％、さらに好ましくは、５×１０-4ｗ/ｖ％〜３×１０-2ｗ/ｖ％である。１×１０−５ｗ/ｖ％未満であると液剤に配合したときの１０−ヒドロキシ−２−デセン酸又はこれを含むローヤルゼリーの薬理作用を発現しにくくなり、１．０ｗ/ｖ％を超えて配合すると内服液剤としたときに風味の点から好ましくないからである。 10-Hydroxy-2-decenoic acid used in the present invention is a known compound, and may be an extract from a royal jelly or a synthetic product, or may be formulated in the form of a royal jelly containing the same. . The amount is 1 × 10 −5 to 1.0 w / v%, preferably 1 × 10 −5 to 1 × 10 −1 w / v%, more preferably 5 × 10 − 4 w / v% to 3 × 10 −2 w / v%. When it is less than 1 × 10 −5 w / v%, it becomes difficult to express the pharmacological action of 10-hydroxy-2-decenoic acid or a royal jelly containing the same when blended in a liquid, and exceeds 1.0 w / v%. This is because when blended, it is not preferable from the viewpoint of flavor when it is used as an internal solution.
本発明におけるポリオキシエチレン基を有する界面活性剤は、例えば、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレングリセリン脂肪酸エステル等が挙げられるが、可溶化力が優れている点からポリオキシエチレン硬化ヒマシ油が特に好ましい。 Examples of the surfactant having a polyoxyethylene group in the present invention include polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene glycerin fatty acid ester, and the like, but the solubilizing power is excellent. To polyoxyethylene hydrogenated castor oil is particularly preferred.
本発明における生薬は、白ジュツ、川キュウ、冬虫夏草、柴胡からなる群より１種又は２種以上を選択することができる。 The herbal medicine in this invention can select 1 type (s) or 2 or more types from the group which consists of white jutsu, river cucumber, cordyceps and saiko.
生薬の配合量は、１０−ヒドロキシ−２−デセン酸１重量部に対して、白ジュツが原生薬換算量で１〜２００００重量部、好ましくは１０〜２０００重量部、川キュウが原生薬換算量で０．１〜１００００重量部、好ましくは１〜１０００重量部、冬虫夏草が原生薬換算量で０．１〜１２０００重量部、好ましくは１〜１２００重量部、柴胡が原生薬換算量で０．２〜４００００重量部、好ましくは２〜４０００重量部である。 The compounding amount of the crude drug is 1 to 20000 parts by weight, preferably 10 to 2000 parts by weight in terms of the bulk drug, and 10 to 2000 parts by weight in terms of the bulk drug, based on 1 part by weight of 10-hydroxy-2-decenoic acid. 0.1 to 10000 parts by weight, preferably 1 to 1000 parts by weight, Cordyceps is 0.1 to 12000 parts by weight in terms of active ingredient, preferably 1 to 1200 parts by weight, and Shiba is 0. 2 to 40,000 parts by weight, preferably 2 to 4000 parts by weight.
配合する生薬は、エキスの形態が好ましい。エキスの製造は通常の方法、例えば、抽出溶媒を用いて、適当な温度（低温又は加熱）にて、生薬原料から抽出する方法などにより行う。抽出溶媒は生薬に応じて適宜選択できるが、好ましくは、水、親水性溶媒（特にエタノール）およびこれらの混合溶媒が用いられる。本発明のエキスとしては、液状抽出物をそのまま使用できるほか、水などで希釈したもの、液状抽出物の濃縮物、液状抽出物の乾固物としても使用できる。すなわち、本発明のエキスは、乾燥エキス、軟エキス、流エキス、チンキなどいずれのものも包含する。 The herbal medicine to be blended is preferably in the form of an extract. The extract is produced by an ordinary method, for example, a method of extracting from a crude drug raw material at an appropriate temperature (low temperature or heating) using an extraction solvent. The extraction solvent can be appropriately selected according to the crude drug, but preferably water, a hydrophilic solvent (especially ethanol) and a mixed solvent thereof are used. As the extract of the present invention, a liquid extract can be used as it is, and it can also be used as a diluted product of water or the like, a concentrate of a liquid extract, or a dried product of a liquid extract. That is, the extract of the present invention includes any of a dry extract, a soft extract, a flow extract, a tincture and the like.
本発明の液剤組成物は、飲料としたときの防腐性、風味等を考慮し、通常ｐＨ２〜７、好ましくはｐＨ２．５〜６程度である。 The liquid composition of the present invention is usually about pH 2 to 7, preferably about pH 2.5 to 6, considering antiseptic properties and flavor when used as a beverage.
本発明の液体組成物は、乳糖、ショ糖、果糖、ブドウ糖、ソルビトール、マルチトール、エリスリトール、キシリトール、トレハロース、ステビア抽出物、スクラロース、アセスルファムカリウム等を甘味剤またはエネルギー源として配合することが出来る。 The liquid composition of the present invention can contain lactose, sucrose, fructose, glucose, sorbitol, maltitol, erythritol, xylitol, trehalose, stevia extract, sucralose, acesulfame potassium, etc. as a sweetening agent or energy source.
また、その他の成分として、ビタミン類、ミネラル類、生薬および生薬抽出物、カフェイン、コンドロイチン硫酸ナトリウムなどを本発明の効果を損なわない範囲で配合することが出来る。 As other components, vitamins, minerals, herbal medicines and herbal extracts, caffeine, sodium chondroitin sulfate, and the like can be blended as long as the effects of the present invention are not impaired.
また、必要に応じて他の公知の添加剤、例えば、抗酸化剤、着色剤、香料、矯味剤、保存料、ｐＨ調整剤などの製剤技術一般に使用される物質を配合することができ、また、界面活性剤などを溶解補助剤として本発明の効果を損なわない範囲で配合することができる。 In addition, other known additives, for example, antioxidants, coloring agents, flavoring agents, flavoring agents, preservatives, pH adjusting agents, and other substances commonly used in pharmaceutical technology can be blended as necessary. Further, a surfactant or the like can be added as a solubilizing agent within a range not impairing the effects of the present invention.
本発明の液体組成物は常法により調製することができ、その方法は特に限定されるものではない。通常、各成分をとり適量の精製水で溶解させた後、ｐＨを調整し、残りの精製水を加えて全量調整する。 The liquid composition of the present invention can be prepared by a conventional method, and the method is not particularly limited. Usually, after each component is taken and dissolved with an appropriate amount of purified water, the pH is adjusted, and the remaining purified water is added to adjust the total amount.
本発明の液体組成物は、例えば健康飲料、栄養補給飲料などの各種飲料、ドリンク剤、シロップ剤などの医薬品や医薬部外品の内服液剤に適用できる。 The liquid composition of the present invention can be applied to, for example, various beverages such as health beverages and nutritional supplement beverages, pharmaceuticals such as drinks and syrups, and internal solutions for quasi drugs.
以下実施例および比較例により、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail by way of examples and comparative examples.
表１の処方に従い常法により、液体組成物を得た。
ただし、１０−ヒドロキシ−２−デセン酸は、生ローヤルゼリー２００ｍｇに１０倍量の精製水を加え、クエン酸ＮａでｐＨ５．０に調整し、９０度で３０分加温攪拌後に遠心分離（日立工機製Ｈｉｍａｃ ＣＴ５ＤＬ、ロータ：ＲＴ３Ｓ（スイング）、３０００ｒｐｍ×２０分）し、上澄み液から得た。
A liquid composition was obtained by a conventional method according to the formulation in Table 1.
However, 10-hydroxy-2-decenoic acid was added to 200 mg of fresh royal jelly with 10 times the amount of purified water, adjusted to pH 5.0 with sodium citrate, heated at 90 degrees for 30 minutes and then centrifuged (Hitachi Machined Himac CT5DL, rotor: RT3S (swing), 3000 rpm × 20 minutes) and obtained from the supernatant.
比較例１及び実施例1から４で得た液体組成物を６５℃恒温槽にて1週間保管後、１０−ヒドロキシ−２−デセン酸含量を液体クロマトグラフ法により定量した。調製直後の１０−ヒドロキシ−２−デセン酸含量に対する６５度、７日間後の残存率（％）を表２に示した。その結果、白ジュツ、川キュウ、冬虫夏草、柴胡からなる群より選ばれる１種又は２種以上の生薬を配合することにより、優れた１０−ヒドロキシ−２−デセン酸の安定化効果が得られた。 The liquid compositions obtained in Comparative Example 1 and Examples 1 to 4 were stored in a constant temperature bath at 65 ° C. for 1 week, and then the 10-hydroxy-2-decenoic acid content was quantified by liquid chromatography. Table 2 shows the residual rate (%) after 65 days and 7 days with respect to the 10-hydroxy-2-decenoic acid content immediately after preparation. As a result, an excellent 10-hydroxy-2-decenoic acid stabilizing effect can be obtained by blending one or more herbal medicines selected from the group consisting of white jutsu, river cucumber, cordyceps and saiko. It was.
本発明によりポリオキシエチレン基を有する界面活性剤を配合した液体組成物に１０−ヒドロキシ−２−デセン酸を安定に配合することが可能になったことから内服液剤等の医薬品や医薬部外品として有用である。
According to the present invention, 10-hydroxy-2-decenoic acid can be stably added to a liquid composition containing a surfactant having a polyoxyethylene group. Useful as.
Claims (3)
A liquid composition comprising a surfactant having a polyoxyethylene group and 10-hydroxy-2-decenoic acid, and one or more herbal medicines selected from the group consisting of white jutsu, river cucumber, cordyceps, and shiihou Method for stabilizing 10-hydroxy-2-decenoic acid by adding.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005247332A JP4911278B2 (en) | 2005-08-29 | 2005-08-29 | Liquid composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005247332A JP4911278B2 (en) | 2005-08-29 | 2005-08-29 | Liquid composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007063144A true JP2007063144A (en) | 2007-03-15 |
| JP4911278B2 JP4911278B2 (en) | 2012-04-04 |
Family
ID=37925737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005247332A Expired - Fee Related JP4911278B2 (en) | 2005-08-29 | 2005-08-29 | Liquid composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4911278B2 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03167113A (en) * | 1989-11-24 | 1991-07-19 | Mirubon:Kk | Hair regenerating agent |
| JPH04134032A (en) * | 1990-09-25 | 1992-05-07 | Shiga Pref Gov Seiyaku Kk | Stable icariin-containing oral solution |
| JPH0948735A (en) * | 1995-08-07 | 1997-02-18 | Kiichi Kubo | Production of crude medicine-containing aqueous liquid agent |
| JPH0959161A (en) * | 1995-08-23 | 1997-03-04 | Taisho Pharmaceut Co Ltd | Fatigue improving composition |
| KR20020092082A (en) * | 2001-06-02 | 2002-12-11 | 김원규 | Tonic composition |
| JP2003231647A (en) * | 2002-02-05 | 2003-08-19 | Maruzen Pharmaceut Co Ltd | Oral liquid composition |
-
2005
- 2005-08-29 JP JP2005247332A patent/JP4911278B2/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03167113A (en) * | 1989-11-24 | 1991-07-19 | Mirubon:Kk | Hair regenerating agent |
| JPH04134032A (en) * | 1990-09-25 | 1992-05-07 | Shiga Pref Gov Seiyaku Kk | Stable icariin-containing oral solution |
| JPH0948735A (en) * | 1995-08-07 | 1997-02-18 | Kiichi Kubo | Production of crude medicine-containing aqueous liquid agent |
| JPH0959161A (en) * | 1995-08-23 | 1997-03-04 | Taisho Pharmaceut Co Ltd | Fatigue improving composition |
| KR20020092082A (en) * | 2001-06-02 | 2002-12-11 | 김원규 | Tonic composition |
| JP2003231647A (en) * | 2002-02-05 | 2003-08-19 | Maruzen Pharmaceut Co Ltd | Oral liquid composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4911278B2 (en) | 2012-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5359218B2 (en) | Beverage | |
| JP5839681B2 (en) | Liquid composition containing herbal extract | |
| JP2015091768A (en) | Liver hydrolysate-containing liquid composition | |
| KR101523586B1 (en) | Pharmaceutical composition for preventing or treating prostatic hyperplasia and preparation method thereof | |
| JP5696720B2 (en) | Beverage | |
| JP2015149918A (en) | beverage | |
| JP2002363105A (en) | Method for masking unpleasant taste and solution for oral administration | |
| JP2011195531A (en) | Protein glycation inhibitor | |
| JP6552097B2 (en) | Bitterness improving agent for food and drink, method for improving bitterness for food and drink, and composition for food and drink | |
| JP2004159563A (en) | Propolis composition | |
| JP4974553B2 (en) | Acetaldehyde metabolism promoter | |
| JP6124710B2 (en) | Preparation with saw palmetto extract | |
| JP4911278B2 (en) | Liquid composition | |
| KR20200036715A (en) | Composition for improving fatigue recovery or exercise performance comprising angelica gigas nakai extract, cnidium officinale makino extract and paeonia japonica extract | |
| KR20150115448A (en) | Preparation for relieving hangover comprising Curcumin | |
| BE1026122B1 (en) | Composition for preventing or reducing the effects of alcohol poisoning | |
| JP6858675B2 (en) | Foods and drinks containing amperopsin and polyglutamic acid | |
| JP5359527B2 (en) | Beverage | |
| JP2002193825A (en) | Liquid composition | |
| JP2021070639A (en) | Composition | |
| JP2021070640A (en) | Liquid or semisolid composition | |
| JP2008127371A (en) | Stable internal liquid medicine composition | |
| JP7267860B2 (en) | Oral composition and manufacturing method thereof | |
| JP7349424B2 (en) | Composition | |
| WO2008075649A1 (en) | Food or drink, quasi drug and medicinal composition for promoting hair growth and method of promoting hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080725 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111221 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120103 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4911278 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150127 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150127 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |